|
1
|
Rosenberg B, VanCamp L, Trosko JE and
Mansour VH: Platinum compounds: A new class of potent antitumour
agents. Nature. 222:385–386. 1969. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jamieson ER and Lippard SJ: Structure,
recognition, and processing of cisplatin-DNA adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar
|
|
3
|
Giacchetti S, Perpoint B, Zidani R, Le
Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y,
Coudert B, et al: Phase III multicenter randomized trial of
oxaliplatin added to chronomodulated fluorouracil-leucovorin as
first-line treatment of metastatic colorectal cancer. J Clin Oncol.
18:136–147. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vasey PA, Paul J, Birt A, Junor EJ, Reed
NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R, et al
Scottish Gynaecological Cancer Trials Group: Docetaxel and
cisplatin in combination as first-line chemotherapy for advanced
epithelial ovarian cancer. J Clin Oncol. 17:2069–2080. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Santos NA, Catão CS, Martins NM, Curti C,
Bianchi ML and Santos AC: Cisplatin-induced nephrotoxicity is
associated with oxidative stress, redox state unbalance, impairment
of energetic metabolism and apoptosis in rat kidney mitochondria.
Arch Toxicol. 81:495–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Macciò A and Madeddu C: Cisplatin : An old
drug with a newfound efficacy - from mechanisms of action to
cytotoxicity. Expert Opin Pharmacother. 14:1839–1857. 2013.
View Article : Google Scholar
|
|
10
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kelland LR, Sharp SY, O'Neill CF, Raynaud
FI, Beale PJ and Judson IR: Mini-review: Discovery and development
of platinum complexes designed to circumvent cisplatin resistance.
J Inorg Biochem. 77:111–115. 1999. View Article : Google Scholar
|
|
12
|
Wong E and Giandomenico CM: Current status
of platinum-based antitumor drugs. Chem Rev. 99:2451–2466. 1999.
View Article : Google Scholar
|
|
13
|
Martín M: Platinum compounds in the
treatment of advanced breast cancer. Clin Breast Cancer. 2:190–209.
2001. View Article : Google Scholar
|
|
14
|
Cosaert J and Quoix E: Platinum drugs in
the treatment of non-small-cell lung cancer. Br J Cancer.
87:825–833. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al-Lazikani B, Banerji U and Workman P:
Combinatorial drug therapy for cancer in the post-genomic era. Nat
Biotechnol. 30:679–692. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chong CR and Sullivan DJ Jr: New uses for
old drugs. Nature. 448:645–646. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weir SJ, DeGennaro LJ and Austin CP:
Repurposing approved and abandoned drugs for the treatment and
prevention of cancer through public-private partnership. Cancer
Res. 72:1055–1058. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pessetto ZY, Weir SJ, Sethi G, Broward MA
and Godwin AK: Drug repurposing for gastrointestinal stromal tumor.
Mol Cancer Ther. 12:1299–1309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mathews Griner LA, Guha R, Shinn P, Young
RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB,
et al: High-throughput combinatorial screening identifies drugs
that cooperate with ibrutinib to kill activated B-cell-like diffuse
large B-cell lymphoma cells. Proc Natl Acad Sci USA. 111:2349–2354.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan S, Wang F, Chen G, Zhang H, Feng L,
Wang L, Colman H, Keating MJ, Li X, Xu RH, et al: Effective
elimination of cancer stem cells by a novel drug combination
strategy. Stem Cells. 31:23–34. 2013. View Article : Google Scholar :
|
|
22
|
Di Pasqua AJ, Hong C, Wu MY, McCracken E,
Wang X, Mi L and Chung FL: Sensitization of non-small cell lung
cancer cells to cisplatin by naturally occurring isothiocyanates.
Chem Res Toxicol. 23:1307–1309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Spigel DR and Greco FA: Chemotherapy in
metastatic and locally advanced non-small cell lung cancer. Semin
Surg Oncol. 21:98–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hata F, Sasaki K, Hirata K, Yamamitsu S
and Shirasaka T: Efficacy of a continuous venous infusion of
fluorouracil and daily divided dose cisplatin as adjuvant therapy
in resectable colorectal cancer: A prospective randomized trial.
Surg Today. 38:623–632. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pommier Y: Topoisomerase I inhibitors:
Camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang JC: Cellular roles of DNA
topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol.
3:430–440. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Staker BL, Hjerrild K, Feese MD, Behnke
CA, Burgin AB Jr and Stewart L: The mechanism of topoisomerase I
poisoning by a camptothecin analog. Proc Natl Acad Sci USA.
99:15387–15392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Redon C, Pilch D, Rogakou E, Sedelnikova
O, Newrock K and Bonner W: Histone H2A variants H2AX and H2AZ. Curr
Opin Genet Dev. 12:162–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Furuta T, Takemura H, Liao ZY, Aune GJ,
Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT,
et al: Phosphorylation of histone H2AX and activation of Mre11,
Rad50, and Nbs1 in response to replication-dependent DNA
double-strand breaks induced by mammalian DNA topoisomerase I
cleavage complexes. J Biol Chem. 278:20303–20312. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Costa RM, Chiganças V, Galhardo RS,
Carvalho H and Menck CF: The eukaryotic nucleotide excision repair
pathway. Biochimie. 85:1083–1099. 2003. View Article : Google Scholar
|
|
31
|
Komuro Y, Udagawa Y, Susumu N, Aoki D,
Kubota T and Nozawa S: Paclitaxel and SN-38 overcome cisplatin
resistance of ovarian cancer cell lines by down-regulating the
influx and efflux system of cisplatin. Jpn J Cancer Res.
92:1242–1250. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stordal B, Pavlakis N and Davey R:
Oxaliplatin for the treatment of cisplatin-resistant cancer: A
systematic review. Cancer Treat Rev. 33:347–357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Terakawa T, Miyake H, Yokoyama N, Miyazaki
A, Tanaka H, Inoue T and Fujisawa M: Clinical outcome of paclitaxel
and carboplatin as second-line chemotherapy for advanced urothelial
carcinoma resistant to first-line therapy with gemcitabine and
cisplatin. Urol Int. 92:180–185. 2014. View Article : Google Scholar
|
|
34
|
Small BG, McColl BW, Allmendinger R, Pahle
J, López-Castejón G, Rothwell NJ, Knowles J, Mendes P, Brough D and
Kell DB: Efficient discovery of anti-inflammatory small- molecule
combinations using evolutionary computing. Nat Chem Biol.
7:902–908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pignata S, Cannella L, Leopardo D, Pisano
C, Bruni GS and Facchini G: Chemotherapy in epithelial ovarian
cancer. Cancer Lett. 303:73–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Murray HW, Pépin J, Nutman TB, Hoffman SL
and Mahmoud AA: Tropical medicine. BMJ. 320:490–494. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schulert AR, Rassoul AA, Mansour M, Girgis
N, McConnell E and Farid Z: Biological disposition of
antibilharzial antimony drugs. II. Antimony fate and uptake by
Schistosoma haematobium eggs in man. Exp Parasitol. 18:397–402.
1966. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Duffin J and Campling BG: Therapy and
disease concepts: The history (and future?) of antimony in cancer.
J Hist Med Allied Sci. 57:61–78. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lecureur V, Lagadic-Gossmann D and Fardel
O: Potassium antimonyl tartrate induces reactive oxygen
species-related apoptosis in human myeloid leukemic HL60 cells. Int
J Oncol. 20:1071–1076. 2002.PubMed/NCBI
|
|
40
|
Lecureur V, Le Thiec A, Le Meur A, Amiot
L, Drenou B, Bernard M, Lamy T, Fauchet R and Fardel O: Potassium
antimonyl tartrate induces caspase- and reactive oxygen
species-dependent apoptosis in lymphoid tumoral cells. Br J
Haematol. 119:608–615. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang B, Yu W, Guo J, Jiang X, Lu W, Liu M
and Pang X: The antiparasitic drug, potassium antimony tartrate,
inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung
cancer. J Pharmacol Exp Ther. 352:129–138. 2015. View Article : Google Scholar
|
|
42
|
Weiss S and Hatcher RA: The mechanism of
the vomiting induced by antimony and Potassium tartrate (Tartar
emetic). J Exp Med. 37:97–111. 1923. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Haldar AK, Sen P and Roy S: Use of
antimony in the treatment of leishmaniasis: Current status and
future directions. Mol Biol Int. 2011:5712422011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Robati M, Holtz D and Dunton CJ: A review
of topotecan in combination chemotherapy for advanced cervical
cancer. Ther Clin Risk Manag. 4:213–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Riemsma R, Simons JP, Bashir Z, Gooch CL
and Kleijnen J: Systematic review of topotecan (Hycamtin) in
relapsed small cell lung cancer. BMC Cancer. 10:4362010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Boabang P, Kurbacher CM, Kohlhagen H,
Waida A and Amo-Takyi BK: Anti-neoplastic activity of topotecan
versus cisplatin, etoposide and paclitaxel in four squamous cell
cancer cell lines of the female genital tract using an ATP-tumor
chemo-sensitivity assay. Anticancer Drugs. 11:843–848. 2000.
View Article : Google Scholar
|
|
47
|
Chou TC, Motzer RJ, Tong Y and Bosl GJ:
Computerized quantitation of synergism and antagonism of taxol,
topotecan, and cisplatin against human teratocarcinoma cell growth:
A rational approach to clinical protocol design. J Natl Cancer
Inst. 86:1517–1524. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fiorica JV: The role of topotecan in the
treatment of advanced cervical cancer. Gynecol Oncol. 90:S16–S21.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brave M, Dagher R, Farrell A, Abraham S,
Ramchandani R, Gobburu J, Booth B, Jiang X, Sridhara R, Justice R,
et al: Topotecan in combination with cisplatin for the treatment of
stage IVB, recurrent, or persistent cervical cancer. Oncology.
20:1401–1404. 1410–1411. 1415–1406. 2006.PubMed/NCBI
|
